Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.creator | Boguszewski, Cesar L. | - |
Autor(es): dc.creator | Huayllas, Martha Katherine P | - |
Autor(es): dc.creator | Vilar, Lucio | - |
Autor(es): dc.creator | Naves, Luciana Ansaneli | - |
Autor(es): dc.creator | Ribeiro-Oliveira Junior, Antonio | - |
Autor(es): dc.creator | Soares, Beatriz Santana | - |
Autor(es): dc.creator | Czepielewski, Mauro Antonio | - |
Autor(es): dc.creator | Abucham, Julio | - |
Autor(es): dc.creator | Correa-Silva, Silvia Regina | - |
Autor(es): dc.creator | Bronstein, Marcello Delano | - |
Autor(es): dc.creator | Jallad, Raquel Soares | - |
Autor(es): dc.creator | Duarte, Felipe Gaia | - |
Autor(es): dc.creator | Musolino, Nina Rosa | - |
Autor(es): dc.creator | Kasuki, Leandro | - |
Autor(es): dc.creator | Gadelha, Monica Roberto | - |
Data de aceite: dc.date.accessioned | 2024-10-23T15:38:44Z | - |
Data de disponibilização: dc.date.available | 2024-10-23T15:38:44Z | - |
Data de envio: dc.date.issued | 2020-01-23 | - |
Data de envio: dc.date.issued | 2020-01-23 | - |
Data de envio: dc.date.issued | 2019 | - |
Fonte completa do material: dc.identifier | https://repositorio.unb.br/handle/10482/36696 | - |
Fonte completa do material: dc.identifier | https://doi.org/10.20945/2359-3997000000159 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0001-7285-7941 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0002-1042-5083 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0003-4815-6963 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0002-3363-3803 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0002-5686-7899 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0002-6114-5786 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0001-5083-5776 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0003-4804-1525 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0003-2405-0013 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0002-0113-5201 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0003-0477-1892 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0002-3495-1301 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0003-1562-4476 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0003-1339-3192 | - |
Fonte completa do material: dc.identifier | http://orcid.org/0000-0002-9250-3558 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/888281 | - |
Descrição: dc.description | Objective Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study. Subjects and methods Characteristics of acromegaly patients treated with PEGV were reviewed at diagnosis, just before and during treatment. All patients with at least two IGF-I measurements on PEGV were included. Efficacy was defined as any normal IGF-I measurement during treatment. Safety data were reviewed. Predictors of response were determined by comparing controlled versus uncontrolled patients. Results 109 patients [61 women; median age at diagnosis 34 years; 95.3% macroadenomas] from 10 Brazilian centers were studied. Previous treatment included surgery (89%), radiotherapy (34%), somatostatin receptor ligands (99%), and cabergoline (67%). Before PEGV, median levels of GH, IGF-I and IGF-I % of upper limit of normal were 4.3 µg/L, 613 ng/mL, and 209%, respectively. Pre-diabetes/diabetes was present in 48.6% and tumor remnant in 71% of patients. Initial dose was 10 mg/day in all except 4 cases, maximum dose was 30 mg/day, and median exposure time was 30.5 months. PEGV was used as monotherapy in 11% of cases. Normal IGF-I levels was obtained in 74.1% of patients. Glycemic control improved in 56.6% of patients with pre-diabetes/diabetes. Exposure time, pre-treatment GH and IGF-I levels were predictors of response. Tumor enlargement occurred in 6.5% and elevation of liver enzymes in 9.2%. PEGV was discontinued in 6 patients and 3 deaths unrelated to the drug were reported. Conclusions In a real-life scenario, PEGV is a highly effective and safe treatment for acromegaly patients not controlled with other therapies. | - |
Descrição: dc.description | Faculdade de Medicina (FMD) | - |
Formato: dc.format | application/pdf | - |
Idioma: dc.language | en | - |
Publicador: dc.publisher | Sociedade Brasileira de Endocrinologia e Metabologia | - |
Direitos: dc.rights | Acesso Aberto | - |
Direitos: dc.rights | (CC BY) - This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | - |
Palavras-chave: dc.subject | Acromegalia | - |
Palavras-chave: dc.subject | Somatotropina | - |
Palavras-chave: dc.subject | Pegvisomanto | - |
Palavras-chave: dc.subject | Estudo multicêntrico | - |
Título: dc.title | Brazilian multicenter study on pegvisomant treatment in acromegaly | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional – UNB |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: